Subject(s)
Neurofibromatosis 1/complications , Sturge-Weber Syndrome/complications , Adult , Humans , MaleABSTRACT
La capecitabina es un agente antineoplásico utilizado para el tratamiento de pacientes con metástasis de tumores sólidos (mama y colon) en estadio avanzado. Se reconocen distintos efectos adversos, entre los cuales se encuentran los cutáneo-mucosos y, en concreto, la hiperpigmentación. Presentamos un caso de hiperpigmentación cutánea localizada secundaria a capecitabina en una mujer intervenida de cáncer de mama y en tratamiento durante un mes con este fármaco. El inicio del tratamiento se asoció con disestesias a nivel de manos y pies, así como aumento de la pigmentación de las mismas. La etiopatogénesis de tales manifestaciones es desconocida. Otros efectos adversos descritos, desde el punto de vista dermatológico, asociados a este fármaco asientan en uñas produciendo onicolisis, fragilidad, decoloración y distrofia
Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon). Different adverse effects have been recognized, among which we find the muco-cutaneous ones and, specifically, hyperpigmentation. We report a case of localized cutaneous hyperpigmentation secondary to capecitabine in a woman that underwent surgery for breast cancer and was receiving this drug for a month. The start of therapy was associated with dysesthesias and hyperpigmentation of the hands and feet. The pathogenesis of such manifestations is unknown. Other reported cutaneous adverse effects associated with this drug involve the nails producing onycholysis, fragility, discoloration and dystrophy
Subject(s)
Female , Middle Aged , Humans , Hyperpigmentation/chemically induced , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapyABSTRACT
Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon). Different adverse effects have been recognized, among which we find the muco-cutaneous ones and, specifically, hyperpigmentation. We report a case of localized cutaneous hyperpigmentation secondary to capecitabine in a woman that underwent surgery for breast cancer and was receiving this drug for a month. The start of therapy was associated with dysesthesias and hyperpigmentation of the hands and feet. The pathogenesis of such manifestations is unknown. Other reported cutaneous adverse effects associated with this drug involve the nails producing onycholysis, fragility, discoloration and dystrophy.
